Company profile

Theranexus specializes in the research and development of therapeutic products for the treatment of diseases affecting the central nervous system. At the end of 2019, the group had a portfolio of 3 products in clinical development phase, including 1 in phase II (THN102; treatment of narcolepsy-related sleep-wake disorders and Parkinson's disease) and 2 in phase I (THN101 for the treatment of neuropathic pain and THN201 for the treatment of neurocognitive disorders in Alzheimer's disease).

Source: Cofisem - Last Update: 03 Nov 2020
Key Executives
Chairman and Chief Executive Officer Franck Mouthon
Deputy CEO Mathieu Charveriat
Administrative & Finance Director Thierry Lambert
Human Resources Director Françoise Vincent-Larrode
Source: Cofisem - Last Update: 02 Jun 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Consumed purchases
Personnal costs 2,353 2,118 1,370 689 542
Operating profit -7,377 -6,990 -2,719 -2,058 -1,116
Income tax -2,038 -1,721 730 583 -605
Net income -5,580 -5,301 -2,115 -1,587 -519
Net consolidated income (Group share) -5,580 -5,301 -2,115 -1,587 -519
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 03 Nov 2020
Shareholder information
Free float 38.30 %
Auriga Partners 17.70 %
Supernova Invest 13.70 %
Mathieu Charveriat 8.80 %
Franck Mouthon 8.80 %
Sofimac Régions 8.40 %
Kreaxi 4.20 %
Employees 0.10 %
Source: Cofisem - Last Update: 22 Jul 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Theranexus

Pépinière Laennec 60 Avenue Rockefeller
FR-69008 Lyon
France
Phone number: +33 (0)1 46 54 98 96
Source: Cofisem - Last Update: 03 Nov 2020

Contact

LAMBERT THIERRY
Phone number: +33 1 46 54 98 96
Source: Theranexus - Last Update: 03 Nov 2020